These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

177 related articles for article (PubMed ID: 12738420)

  • 1. Rewiring the T-cell: signaling defects and novel prospects for the treatment of SLE.
    Tsokos GC; Nambiar MP; Tenbrock K; Juang YT
    Trends Immunol; 2003 May; 24(5):259-63. PubMed ID: 12738420
    [No Abstract]   [Full Text] [Related]  

  • 2. Altered T and B lymphocyte signaling pathways in lupus.
    Peng SL
    Autoimmun Rev; 2009 Jan; 8(3):179-83. PubMed ID: 18721908
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Decreased SAP Expression in T Cells from Patients with Systemic Lupus Erythematosus Contributes to Early Signaling Abnormalities and Reduced IL-2 Production.
    Karampetsou MP; Comte D; Kis-Toth K; Terhorst C; Kyttaris VC; Tsokos GC
    J Immunol; 2016 Jun; 196(12):4915-24. PubMed ID: 27183584
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The IL-2 defect in systemic lupus erythematosus disease has an expansive effect on host immunity.
    Lieberman LA; Tsokos GC
    J Biomed Biotechnol; 2010; 2010():740619. PubMed ID: 20625413
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Reconstitution of deficient T cell receptor zeta chain restores T cell signaling and augments T cell receptor/CD3-induced interleukin-2 production in patients with systemic lupus erythematosus.
    Nambiar MP; Fisher CU; Warke VG; Krishnan S; Mitchell JP; Delaney N; Tsokos GC
    Arthritis Rheum; 2003 Jul; 48(7):1948-55. PubMed ID: 12847689
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pathological lymphocyte activation by defective clearance of self-ligands in systemic lupus erythematosus.
    Yasutomo K
    Rheumatology (Oxford); 2003 Feb; 42(2):214-22. PubMed ID: 12595613
    [TBL] [Abstract][Full Text] [Related]  

  • 7. TCR zeta-chain abnormalities in human systemic lupus erythematosus.
    Nambiar MP; Krishnan S; Warke VG; Tsokos GC
    Methods Mol Med; 2004; 102():49-72. PubMed ID: 15286380
    [TBL] [Abstract][Full Text] [Related]  

  • 8. SLE-Associated Defects Promote Altered T Cell Function.
    Crispin JC; Hedrich CM; Suárez-Fueyo A; Comte D; Tsokos GC
    Crit Rev Immunol; 2017; 37(1):39-58. PubMed ID: 29431078
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Interleukin 2 receptors and responsiveness to recombinant human interleukin 2 in patients with systemic lupus erythematosus.
    Lakhanpal S; Handwerger BS
    Mayo Clin Proc; 1987 Jan; 62(1):3-7. PubMed ID: 3099102
    [TBL] [Abstract][Full Text] [Related]  

  • 10. TCR AV24 gene expression in double negative T cells in systemic lupus erythematosus.
    Sumida T; Maeda T; Taniguchi M; Nishioka K; Stohl W
    Lupus; 1998; 7(8):565-8. PubMed ID: 9863902
    [No Abstract]   [Full Text] [Related]  

  • 11. Systemic lupus erythematosus sera antilymphocyte reactivity: detection of antibodies to Tac-antigen positive T cell lines.
    Sano H; Kumagai S; Namiuchi S; Uchiyama T; Yodoi J; Maeda M; Takatsuki K; Suginoshita T; Imura H
    Clin Exp Immunol; 1986 Jan; 63(1):8-16. PubMed ID: 3006953
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Systemic lupus erythematosus: new molecular targets.
    Crispín JC; Kyttaris V; Juang YT; Tsokos GC
    Ann Rheum Dis; 2007 Nov; 66 Suppl 3(Suppl 3):iii65-9. PubMed ID: 17934100
    [TBL] [Abstract][Full Text] [Related]  

  • 13. T cells as a therapeutic target in SLE.
    Comte D; Karampetsou MP; Tsokos GC
    Lupus; 2015 Apr; 24(4-5):351-63. PubMed ID: 25801878
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Enhanced CD3-mediated T lymphocyte proliferation in patients with systemic lupus erythematosus.
    Stekman IL; Blasini AM; Leon-Ponte M; Baroja ML; Abadi I; Rodriguez MA
    Arthritis Rheum; 1991 Apr; 34(4):459-67. PubMed ID: 1826426
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Impaired T-cell activation in patients with systemic lupus erythematosus.
    Sierakowski S; Kucharz EJ; Lightfoot RW; Goodwin JS
    J Clin Immunol; 1989 Nov; 9(6):469-76. PubMed ID: 2517125
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Identification of microRNA-31 as a novel regulator contributing to impaired interleukin-2 production in T cells from patients with systemic lupus erythematosus.
    Fan W; Liang D; Tang Y; Qu B; Cui H; Luo X; Huang X; Chen S; Higgs BW; Jallal B; Yao Y; Harley JB; Shen N
    Arthritis Rheum; 2012 Nov; 64(11):3715-25. PubMed ID: 22736314
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Characterization of T lymphocyte subpopulations responsible for deficient interleukin 2 activity in patients with systemic lupus erythematosus.
    Murakawa Y; Takada S; Ueda Y; Suzuki N; Hoshino T; Sakane T
    J Immunol; 1985 Jan; 134(1):187-95. PubMed ID: 3917275
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Systemic lupus erythematosus: all roads lead to type I interferons.
    Pascual V; Farkas L; Banchereau J
    Curr Opin Immunol; 2006 Dec; 18(6):676-82. PubMed ID: 17011763
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Abnormal expression of various molecular forms and distribution of T cell receptor zeta chain in patients with systemic lupus erythematosus.
    Nambiar MP; Enyedy EJ; Fisher CU; Krishnan S; Warke VG; Gilliland WR; Oglesby RJ; Tsokos GC
    Arthritis Rheum; 2002 Jan; 46(1):163-74. PubMed ID: 11817588
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A splice variant of the TCR zeta mRNA lacking exon 7 leads to the down-regulation of TCR zeta, the TCR/CD3 complex, and IL-2 production in systemic lupus erythematosus T cells.
    Tsuzaka K; Setoyama Y; Yoshimoto K; Shiraishi K; Suzuki K; Abe T; Takeuchi T
    J Immunol; 2005 Mar; 174(6):3518-25. PubMed ID: 15749888
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.